Bon Natural Life Ltd 6-K, filed Aug 1, 2022
Bon Natural Life Ltd (BON)
About this 6-K
Bon Natural Life Ltd filed this 6-K on August 1, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of August
Commission
File Number
(Translation of registrant’s name into English)
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Included with this report as Exhibit 99.1 hereto are our unaudited financial results and statements for the six (6) months ended March 31, 2022. Management’s discussion and analysis of our financial condition and results of operations for the semi-annual period ended March 31, 2022 is set forth below:
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our company’s financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes included elsewhere in this filing. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements. All statements contained in this report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the “Risk Factors” section. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
Overview
We are a bio-ingredient solutions provider in the natural, health and personal care industries and are engaged in the research and development, manufacturing and sales of functional active ingredients extracted from natural herb plants which are widely used by manufacturer customers in the functional food, personal care, cosmetic and pharmaceutical industries. We sell our products to customers located in both Chinese and international markets.
Recent Developments
Newly formed subsidiary
On September 8, 2021, Xi’an Youpincui Biotechnology Co., Ltd (“Xi’an Youpincui”) was formed as a Wholly Foreign-Owned Enterprise (“WFOE”) in the People’s Republic of China (“PRC”). Tea Essence Limited, our direct wholly owned subsidiary incorporated in Hong Kong, owns 100% equity interest in Xi’an Youpincui.
Terminating the VIE agreements for corporate restructuring
Due to PRC legal restrictions on foreign ownership in companies that engage in online sales China, we originally carried out our business through Xi’an App-Chem, a domestic PRC company holding a value-added telecommunications license, through a variable interest entity structure, because foreign investment in the value-added telecommunication services industry in China is extensively regulated and subject to numerous restrictions. However, our online sales have historically generated minimal revenues. On September 28, 2021, our Board of Directors approved a restructuring of our corporate structure to terminate the original VIE contractual agreements, to convert Xi’an App-Chem from a PRC domestic company into a Sino-foreign joint venture, and to transfer 100% of the ownership interests in Xi’an App-Chem from its original shareholders to Xi’an CMIT and Xi’an Youpincui. On October 21, 2021, Xi’an Ap-Chem’s original shareholders signed the share transfer agreement to transfer their 100% ownership interest in Xi-an App-Chem to Xi’an CMIT and Xi’an Youpincui. On October 22, 2021, Xi-an App-Chem completed its business license registration with PRC government and became a Sino-foreign joint venture.
Effective November 1, 2021, we completed the reorganization of our corporate structure in the PRC and are the indirect sole shareholder of Xi’an App-Chem. Xi’an App-Chem is wholly-owned by two WOFEs Xi’an CMIT and Xi’an Youpincui. Each of the WOFEs are in turn wholly-owned by Tea Essence, our direct wholly-owned subsidiary in Hong Kong. Xi’an App-Chem’s financial results are consolidated into our consolidated financial statements in accordance with U.S. GAAP because we have control over that entity by way of 100% share ownership through Tea Essence, and in turn, Xi’an CMIT and Xi’an Youpincui. The termination of the VIE agreements as described above does not adversely affect our business, financial condition, and results of operations because we, together with our wholly owned subsidiaries, are effectively controlled by the same shareholders before and after the restructuring. The restructuring is therefore considered to be a recapitalization of entities under common control. Following the corporate restructuring, the value-added telecommunication license held by Xi’an App-Chem has been revoked and we’re investigating other feasible ways to explore online sales business.
COVID-19 Impact
Our business operations have been affected and may continue to be affected by the ongoing COVID-19 pandemic. A resurgence could cause city lockdown, negatively affect the execution of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with COVID 19 may cause our revenue and cash flows to underperform in the next 12 months from the date our unaudited condensed consolidated interim financial statements for the six months ended March 31, 2022 are released. The extent of the future impact of the COVID-19 pandemic on our business and results of operations is still uncertain.
Comparison of Results of Operations for the six months ended March 31, 2022 and 2021
The following table summarizes the results of our operations during the six months ended March 31, 2022 and 2021, respectively, and provides information regarding the dollar and percentage increase or (decrease) during such periods.
| In the Six Months Ended March 31, | ||||||||||||||||||||||||
| 2022 | 2021 | Variance | ||||||||||||||||||||||
| Amount | % of revenue | Amount | % of revenue | Amount | % | |||||||||||||||||||
| REVENUE | $ | 13,688,400 | 100.0 | % | $ | 11,698,830 | 100.0 | % | $ | 1,989,570 | 17.0 | % | ||||||||||||
| COST OF REVENUE | 9,652,453 | 70.5 | % | 8,325,148 | 71.2 | % | 1,327,305 | 15.9 | % | |||||||||||||||
| GROSS PROFIT | 4,035,947 | 29.5 | % | 3,373,682 | 28.8 | % | 662,265 | 19.6 | % | |||||||||||||||
| OPERATING EXPENSES | ||||||||||||||||||||||||
| Selling expenses | 83,970 | 0.6 | % | 52,666 | 0.5 | % | 31,304 | 59.4 | % | |||||||||||||||
| General and administrative expenses | 998,943 | 7.3 | % | 679,635 | 5.8 | % | 319,308 | 47.0 | % | |||||||||||||||
| Research and development expenses | 164,675 | 1.2 | % | 106,998 | 0.9 | % | 57,677 | 53.9 | % | |||||||||||||||
| Total operating expenses | 1,247,588 | 9.1 | % | 839,299 | 7.2 | % | 408,289 | 48.6 | % | |||||||||||||||
| INCOME FROM OPERATIONS | 2,788,359 | 20.4 | % | 2,534,383 | 21.7 | % | 253,976 | 10.0 | % | |||||||||||||||
| OTHER INCOME (EXPENSE) | ||||||||||||||||||||||||
| Interest expense, net | (277,175 | ) | (2.0 | )% | (196,874 | ) | (1.7 | )% | (80,301 | ) | (40.8 | )% | ||||||||||||
| Other income, net | 581,213 | 4.2 | % | 422,767 | 3.6 | % | 158,446 | 37.5 | % | |||||||||||||||
| Total other income (expenses), net | 304,038 | 2.2 | % | 225,893 | 1.9 | % | 78,145 | 34.6 | % | |||||||||||||||
| INCOME BEFORE INCOME TAX PROVISION | 3,092,397 | 22.6 | % | 2,760,276 | 23.6 | % | 332,121 | 12.0 | % | |||||||||||||||
| PROVISION FOR INCOME TAXES | 562,737 | 4.1 | % | 465,077 | 4.0 | % | 97,660 | 21.0 | % | |||||||||||||||
| NET INCOME | $ | 2,529,660 | 18.5 | % | $ | 2,295,199 | 19.6 | % | $ | 234,461 | 10.2 | % | ||||||||||||
Revenues
We currently produce our products for our customers in three broad product categories: fragrance compounds, health supplemental (powder drinks) and bioactive food ingredients.
Total revenues were $13,688,400 in the six months ended March 31, 2022, an increase of $1,989,570, or approximately 17.0% as compared to $11,698,830 in the same period of 2021. Specifically, the increase in revenues was primarily attributable to (i) an increase in average selling price of fragrance compound, health supplemental powder drinks and bioactive food ingredients by 64.1%, 11.2% and 79.2%, respectively, as we raised our selling prices in response to the rising raw material costs and market change as affected by the COVID-19, as well as product mix change of fragrance compounds and bioactive food ingredients; (ii) an increase in sales volume of bioactive food ingredients by 47.5%, due to strong customer demand and our sales effort to promote sales of milk thistle extracts with benefits to protect liver and lower blood sugar; (iii) We sold our products to 87 and 86 customers in the six months ended March 31, 2022 and 2021, respectively. In terms of purchase order size, average purchase order by our customers increased by 15.7% from approximately $136,000 per customer in six months ended March 31, 2021 to approximately $157,000 per customer in six months ended March 31, 2022; For the six months ended March 31, 2022, three customers accounted for 44.0%, 24.4% and 11.2% of the Company’s total revenue, respectively. For the six months ended March 31, 2021, two customers accounted for 40.2% and 37.1% of the Company’s total revenue, respectively; (iv) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022, and (v) partially offset by the decrease in sales volume of our fragrance compounds and health supplemental powder drinks by 26.0% and 37.5%, respectively, in the six months ended March 31, 2022 as compared to the same period of 2021 due to shortage of material supply caused by abnormal wet weather, and disruption of logistics caused by COVID-19 pandemic resurgence in early 2022.
The following table summarizes the breakdown of revenues by categories for the periods indicated.
| Revenues | ||||||||||||||||||||||||
| In the Six Months Ended March 31, | ||||||||||||||||||||||||
| 2022 | 2021 | Change | Change | |||||||||||||||||||||
| Amount | % | Amount | % | Amount | % | |||||||||||||||||||
| Fragrance compounds | $ | 7,438,950 | 54.3 | % | $ | 5,957,386 | 50.9 | % | $ | 1,481,564 | 24.9 | % | ||||||||||||
| Health supplements (powder drinks) | 3,340,530 | 24.4 | % | 4,671,082 | 39.9 | % | (1,330,552 | ) | (28.5 | )% | ||||||||||||||
| Bioactive food ingredients | 2,908,920 | 21.3 | % | 1,070,362 | 9.2 | % | 1,838,558 | 171.8 | % | |||||||||||||||
| Total Revenue | $ | 13,688,400 | 100.0 | % | $ | 11,698,830 | 100.0 | % | $ | 1,989,570 | 17.0 | % | ||||||||||||
Revenues from sales of our fragrance compound products
Our fragrance compound products primarily include natural compounds extracted from plants for cosmetic applications, such as sclareolide and ambroxide, a sustainable replacement to ambergris, a secretion by sperm whales.
Revenues from sales of our fragrance compound products increased by 24.9% or $1,481,564 to $7,438,950 in the six months ended March 31, 2022 from $5,957,386 in the same period of 2021. This increase was attributable to the following: (i) a 64.1% increase in average selling price of our fragrance compound products in response to increased raw materials purchase price as affected by COVID-19 impact and product mix change, we put more selling effort in sales of high value added product ambroxide with higher selling price. Weighted average unit cost for this product category increased by 54.8% in the six months ended March 31, 2022, as compared to that in same period of 2021 mainly due to higher raw material purchase costs and product mix change in 2022; (ii) an increase in average purchase order by our customers by 15.7% in six months ended March 31, 2022 as compared to six months ended March 31, 2021 as discussed above; (iii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022; and (iv) partially offset by a decrease of 26.0% in sales volume from 26,678 kilograms sold in the six months ended March 31, 2021 to 19,729 kilograms sold in the same period of 2022. Our principal raw material, clary sage, which is used to produce sclareolide and ambroxide, is mainly planted in in North China, which suffered abnormal wet weather in the second half of 2021. Along with disruption of logistics caused by COVID-19 pandemic resurgence in early 2022, we have experienced a shortage of material supply for our fragrance compounds in the six months ended March 31, 2022.
Revenues from sales of our health supplement (powder drinks) products
Our health supplement (powder drinks) products primarily include Prebiotics series with benefits such as intestine rejuvenation and probiotic proliferation acceleration.
Revenues from sales of health supplement (powder drinks) products decreased by 28.5% or $1,330,552 to $3,340,530 in the six months ended March 31, 2022 from $4,671,082 in the same period of 2021. This decrease was attributable to the following: (i) a decrease of 37.5% in sales volume from 207,994 cases sold in the six months ended March 31, 2021 to 130,000 cases sold in the same period of 2022. Our principal raw material, stachys affinis, which is used to produce prebiotics, is mainly planted in North China, which suffered abnormal wet weather in the second half of 2021. Along with disruption of logistics caused by COVID-19 pandemic resurgence in early 2022, we have experienced a shortage of material supply for our health supplemental powder drinks in the six months ended March 31, 2022; and partially offset by (ii) a 11.2% increase in average selling price of health supplement (powder drinks) products in response to increased raw materials purchase price as affected by COVID-19 impact and general inflation. Weighted average unit cost for this product category increased by 19.2% in the six months ended March 31, 2022, as compared to that in same period of 2021 mainly due to higher raw material purchase costs in 2022; (iii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022.
Revenues from sales of our bioactive food ingredient products
Our bioactive food ingredient products primarily include fruit juice concentrates and extracts for a variety of health benefits that can’t be sufficiently sourced from daily dietary intakes, such as fruit concentrates, apple polyphenol, rich in anti-oxidant and derived from apple, milk thistle extracts with benefits to protect liver and lower blood sugar, and phloretin, an anti-oxidant with skin discoloration effect extracted from leaves and roots of apple, pear and other fruits.
Revenues from sales of our bioactive food ingredient products increased by 171.8% or $1,838,558 to $2,908,920 in the six months ended March 31, 2022 from $1,070,362 in the same period of 2021. The increase was mainly attributable to the following: (i) a 79.2% increase in average selling price of our bioactive ingredient products as a result of increased raw materials purchase price as affected by COVID-19 impact and market change, as well as change in product mix, more milk thistle extracts products with higher price were sold in the six months ended March 31, 2022; (ii) a 47.5% increase in sales volume from 33,352 kilograms in the six months ended March 31, 2021 to 49,178 kilograms in the same period of 2022 due to strong customer demand and our sales effort to promote sales of milk thistle extracts with benefits to protect liver and lower blood sugar; (iii) an increase in average purchase order by our customers by 15.7% in six months ended March 31, 2022 as compared to six months ended March 31, 2021 as discussed above and (iv) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022.
Cost of Revenues
Our cost of revenues primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and amortization, freight costs and overhead) and business tax. Cost of revenues generally changes as our production costs change, which are affected by factors including the market price of raw materials, or labor productivity, and as the customer and product mix changes.
Our cost of revenues increased by $1,327,305, or 15.9%, from $8,325,148 in the six months ended March 31, 2021 to $9,652,453 in the same period of 2022. The increase in our cost of revenues was mainly attributable to the following: (i) an increase of 54.8%, 19.2% and 72.6% in the average unit cost of our fragrance compound products, health supplement (powder drinks) products and bioactive food ingredients products, respectively, due to the increase in raw material purchase costs, as well as product mix change of fragrance compounds and bioactive food ingredients; (ii) sale volume of our bioactive food ingredients products increased by 47.5% in the six months ended March 31, 2022 compared to the same period of 2021 due to strong customer demand and our sales effort to promote sales of milk thistle extracts with benefits to protect liver and lower blood sugar, and (iii) partially offset by the decrease in sales volume of our fragrance compounds and health supplemental powder drinks by 26.0% and 37.5%, respectively, in the six months ended March 31, 2022 as compared to the same period of 2021 due to shortage of material supply caused by abnormal wet weather in North China and disruption of logistics caused by COVID-19 pandemic resurgence in early 2022 as discussed above.
| In the Six Months Ended March 31, | ||||||||||||||||
| 2022 | 2021 | Change | ||||||||||||||
| Amount | Amount | Amount | % | |||||||||||||
| Cost of revenues – Fragrance compound products | $ | 5,636,789 | $ | 4,786,154 | $ | 850,635 | 17.8 | % | ||||||||
| Cost of revenues – Health supplement (powder drinks) | 2,171,757 | 2,834,500 | (662,743 | ) | (23.4 | )% | ||||||||||
| Cost of revenues – Bioactive food ingredients | 1,843,907 | 704,494 | 1,139,413 | 161.7 | % | |||||||||||
| Total cost of revenues | $ | 9,652,453 | $ | 8,325,148 | $ | 1,327,305 | 15.9 | % | ||||||||
Cost of Revenues from sales of our fragrance compound products
The 17.8% increase in cost of revenues for our fragrance compound products from $4,786,154 in the six months ended March 31, 2021 to $5,636,789 in the same period of 2022 was mainly attributable to the following: (i) an increase of 54.8% in weighted average unit cost for this product category mainly due to higher raw material purchase costs as affected by the COVID-19 impact and product mix change, we put more selling effort in sales of high value added product ambroxide with higher cost of revenue; (ii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022; and (iii) partially offset by a decrease of 26.0% in sales volume from 26,678 kilograms sold in the six months ended March 31, 2021 to 19,729 kilograms sold in the same period of 2022. Our principal raw material, clary sage, which is used to produce sclareolide and ambroxide, is mainly planted in in North China, which suffered abnormal wet weather in the second half of 2021. Along with disruption of logistics caused by COVID-19 pandemic resurgence in early 2022, we have experienced a shortage of material supply for our fragrance compounds in the six months ended March 31, 2022.
Cost of Revenues from sales of our health supplement (powder drinks) products
The 23.4% decrease in cost of revenues for our health supplement (powder drinks) products from $2,834,500 in the six months ended March 31, 2021 to $2,171,757 in the same period of 2022 was mainly attributable to the following: (i) a decrease of 37.5% in sales volume from 207,994 cases sold in the six months ended March 31, 2021 to 130,000 cases sold in the same period of 2022. Our principal raw material, stachys affinis, which is used to produce prebiotics, is mainly planted in North China, which suffered abnormal wet weather in the second half of 2021. Along with disruption of logistics caused by COVID-19 pandemic resurgence in early 2022, we have experienced a shortage of material supply for our health supplemental powder drinks in the six months ended March 31, 2022; and partially offset by (ii) an increase of 19.2% in weighted average unit cost for this product category mainly due to higher raw material purchase costs as affected by the COVID-19 impact and general inflation; (iii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022.
Cost of Revenues from sales of our bioactive food ingredient products
The 161.7% increase in cost of revenues for our bioactive food ingredient products from $704,494 in the six months ended March 31, 2021 to $1,843,907 in the same period of 2022 was mainly attributable to the following: (i) an increase of 72.6% in weighted average unit cost of our bioactive ingredient products as a result of increased raw materials purchase price as affected by COVID-19 impact and general inflation, as well as change in product mix, more milk thistle extracts products with higher average unit cost were sold in the six months ended March 31, 2022; (ii) a 47.5% increase in sales volume from 33,352 kilograms in the six months ended March 31, 2021 to 49,178 kilograms in the same period of 2022 due to strong customer demand and our sales effort to promote sales of milk thistle extracts with benefits to protect liver and lower blood sugar; and (iii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022.
Gross Profit
| In the Six Months Ended March 31, | ||||||||||||||||
| 2022 | 2021 | Change | ||||||||||||||
| Amount | Amount | Amount | % | |||||||||||||
| Gross Profit – Fragrance compound products | $ | 1,802,161 | $ | 1,171,232 | $ | 630,929 | 53.9 | % | ||||||||
| Gross Profit – Health supplement (powder drinks) | 1,168,773 | 1,836,582 | (667,809 | ) | (36.4 | )% | ||||||||||
| Gross Profit – Bioactive food ingredients | 1,065,013 | 365,868 | 699,145 | 191.1 | % | |||||||||||
| Total Gross Profit | $ | 4,035,947 | $ | 3,373,682 | $ | 662,265 | 19.6 | % | ||||||||
| Gross Profit Margin | 29.5 | % | 28.8 | % | 0.7 | % | ||||||||||
Our gross profit in the six months ended March 31, 2022 increased by $662,266, or 19.6%, to $4,035,947, from $3,373,682 in the same period of 2021. Our gross margin increased by 0.7% from 28.8% in the six months ended March 31, 2021 to 29.5% in the same period of 2022. The increase in gross profit was due to (i) an increase of 47.5% in sales volume of bioactive food ingredient products due to stronger demand and change in sales strategy as discussed above; (ii) gross profit margin of our fragrance compound products increased by 4.5 percentage point due to increase in average selling price in response to increased raw materials purchase price and product mix change as discussed above; and (iii) partially offset by the decrease in sales volume of our fragrance compounds and health supplemental powder drinks by 26.0% and 37.5%, respectively, in the six months ended March 31, 2022 as compared to the same period of 2021 due to shortage of material supply as discussed above. The increase in our gross margin by 0.7% from 28.8% in the six months ended March 31, 2021 to 29.5% in the same period of 2022 was due to changes in product mix and increase in selling price.
Gross profit from sales of our fragrance compound products
Gross profit of our fragrance compound products increased by $630,929 or 53.9% from $1,171,233 in the six months ended March 31, 2021 to $1,802,161 in the same period of 2022. The increase was primarily attributable to (i) a 64.1% increase in average selling price of our fragrance compound products in response to increased raw materials purchase price as affected by COVID-19 impact and product mix change as discussed above, while weighted average unit cost for this product category increased by 54.8% in 2022; (ii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022; and (iii) partially offset by a decrease of 26.0% in sales volume due to shortage of material supply as discussed above As a result of the above, gross margin for our fragrance compound products increased by 4.5 percentage point from 19.7% in the six months ended March 31, 2021, to 24.2% in the same period of 2022.
Gross profit from sales of our health supplement (powder drinks) products
Gross profit of our health supplement (powder drinks) products decreased by $667,808 or 36.4% from $1,836,582 in the six months ended March 31, 2021, to $1,168,773 in the same period of 2022. The decrease was primarily attributable to: (i) a decrease of 37.5% in sales volume due to shortage of material supply as discussed above; (ii) weighted average unit cost for this product category increased by 19.2%, while average selling price increased by 11.2% , and partially offset by (iii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022.
Gross profit from sales of our bioactive food ingredient products
Gross profit of our bioactive food ingredient products increased by $699,146 or 191.1%, from $365,867 in the six months ended March 31, 2021, to $1,065,013 in the same period of 2022. This increase was primarily due to (i) a 47.5% increase in sales volume from 33,352 kilograms in the six months ended March 31, 2021 to 49,178 kilograms in the same period of 2022 due to strong customer demand and our sales effort to promote sales of milk thistle extracts with benefits to protect liver and lower blood sugar; (ii) a 79.2% increase in average selling price of our bioactive ingredient products as a result of increased raw materials purchase price as affected by COVID-19 impact and market change, as well as change in product mix, more milk thistle extracts with higher gross margin were sold in the six months ended March 31, 2022, while weighted average unit cost increased by 72.6% compared to the same period of 2021; and (iii) a 2.8% positive impact from foreign currency fluctuation when average exchange rate used in converting RMB into USD changed from US$1 to RMB 6.5541 in the six months ended March 31, 2021 to US$1 to RMB 6.3712 in the same period of 2022.
Selling expenses
| In the six months ended | Change | |||||||||||||||
| (in US dollars, except percentage) | 2022 | 2021 | Amount | % | ||||||||||||
| Selling Expenses | $ | 83,970 | $ | 52,666 | $ | 31,304 | 59.4 | % | ||||||||
| as a percentage of revenues | 0.6 | % | 0.5 | % | 0.1 | % | ||||||||||
Selling expenses increased by $31,304, or 59.4%, from $52,666 in the six months ended March 31, 2021, to $83,970 in the same period of 2022. The COVID-19 outbreak and spread caused reduced trade shows and business travel, and we put more focus to target our customers through online and virtual marketing and sales promotion, our online advertising expense in the six months ended March 31, 2022 increased by $27,774 compared to the same period of 2021.
General and administrative expenses
| In the six months ended | Change | |||||||||||||||
| (in US dollars, except percentage) | 2022 | 2021 | Amount | % | ||||||||||||
| General and Administrative Expenses | $ | 998,943 | $ | 679,635 | $ | 319,308 | 47.0 | % | ||||||||
| as a percentage of revenues | 7.3 | % | 5.8 | % | 1.5 | % | ||||||||||
General and administrative expenses increased by $319,308, or 47.0%, from $679,635 in the six months ended March 31, 2021, to $998,943 in the same period of 2022, mainly attributable to increase of $335,265 in professional service fees such as directors’ and officers’ liability insurance, investor relations management, etc. as we become a public company since we completed the IPO in July 2021.
Research and development (“R&D”) expenses
| In the six months ended | Change | |||||||||||||||
| (in US dollars, except percentage) | 2022 | 2021 | Amount | % | ||||||||||||
| Research and Development Expenses | $ | 164,675 | $ | 106,998 | $ | 57,677 | 53.9 | % | ||||||||
| as a percentage of revenues | 1.2 | % | 0.9 | % | 0.3 | % | ||||||||||
Research and development expenses increased by $57,677, or approximately 53.9%, from $106,998 in the six months ended March 31, 2021, to $164,675 in the same period of 2022. The increase was mainly due to an increase of $69,022 in outsourcing R&D activities to external consulting firms.
Other income (expenses)
Other income (expenses) primarily includes interest income generated from our bank deposits, interest expenses incurred on our borrowings from various banks and financial institutions, government subsidy income, rental income, income from technology transfer, unrealized foreign currency exchange gain due to our export sales, and investment income of short-term investment.
| In the six months ended | Change | |||||||||||||||
| (in US dollars, except percentage) | 2022 | 2021 | Amount | % | ||||||||||||
| Interest expense, net | $ | (277,175 | ) | (196,874 | ) | (80,301 | ) | 40.8 | % | |||||||
| Foreign currency exchange gain (loss) | (16,994 | ) | (65,691 | ) | (48,697 | ) | (74.1 | )% | ||||||||
| Other income, net | ||||||||||||||||
| -Government grants | 542,256 | 446,910 | 95,346 | 21.3 | % | |||||||||||
| -Rental income | 43,532 | 41,548 | 1,984 | 4.8 | % | |||||||||||
| -Investment income | $ | 12,419 | $ | - | $ | 12,419 | 100 | % | ||||||||
Interest expense, net, increased by $80,301, or approximately 40.8% in the six months ended March 31, 2022 as compared to 2021. The increase was mainly attributable to increased average loan balances we carried during the six months ended March 31, 2022 compared to the same period of 2021.
Government subsidy income primarily relate to local government’s cash award to HNTEs based on their financial performance to promote entrepreneurship and stimulate local economies. Such awards are granted on a case-by-case basis by various local governments. Our subsidiary, Xi’an App-chem was approved as a HNTE and received government subsidy in the form of an export sales refund and cash awards based on our annual financial performance. We recognize government subsidies as other operating income when they are received because they are not subject to any past or future conditions, there are no performance conditions or conditions of use, and they are not subject to future refunds. Government subsidies received in the form of a grant and recognized as other operating income totaled $542,256 and $446,910 in the six months ended March 31, 2022 and 2021, respectively.
Our subsidiary, Xi’an App-Chem, leased office space to a third-party and recorded rental income of $43,532 and $41,548 in the six months ended March 31, 2022 and 2021, respectively.
Investment income related to income generated by our short-term investments, amounted to $12,419 and $Nil in the six months ended March 31, 2022 and 2021, respectively.
The overall changes in our other income (expenses) reflected the above major factors.
Provision for Income Taxes
Our provision for income taxes was $562,737 in the six months ended March 31, 2022, an increase of $97,660, or 21.0% from $465,077 in the same period of 2021 due to our increased taxable income. Under the EIT Law, domestic enterprises and FIEs are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. EIT grants preferential tax treatment to “HNTEs”. Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. The corporate income taxes for the six months ended March 31, 2022 and 2021 were reported at a blended reduced rate as a result of Xi’an App-chem being approved as a HNTE and enjoying a 15% reduced income tax rate, but subsidiaries of Xi’an App-chem are subject to a 25% income tax rate. The impact of the tax holidays noted above decreased foreign taxes by $375,177 and $302,123 for the six months ended March 31, 2022 and 2021, respectively. The benefit of the tax holidays on net income per share (basic and diluted) $0.04 and $0.05 for the six months ended March 31, 2022 and 2021, respectively.
Net income
As a result of the foregoing, our net income increased from $2,295,199 in the six months ended March 31, 2021 to $2,529,660 in the same period of 2022.
Liquidity and Capital Resources
As reflected in our unaudited condensed consolidated financial statements, we are currently constructing two new manufacturing plants. As of March 31, 2022, we had future minimum capital expenditure commitment on its construction-in-progress (“CIP”) project of approximately $1.0 million within the next twelve months. We also had large unpaid tax liabilities of approximately $3.3 million, which are expected to be settled with local tax authorities within one year. Furthermore, the ongoing outbreak of COVID-19 may continue to negatively impact our business operations. A resurgence could negatively affect our ability to fulfil customer sales orders and collect customer payments timely, or disrupt our supply chain. As a result, there is a possibility that our revenue and cash flows may underperform in the next 12 months.
In assessing its liquidity, management monitors and analyzes our cash on-hand, our ability to generate sufficient revenue sources in the future, and our operating and capital expenditure commitments. In June 2021, we closed the initial public offering and received net proceeds of approximately $11.3 million.
As of March 31, 2022, we had cash on hand of $1.6 million. We also had outstanding accounts receivable of approximately $7.5 million, of which approximately $7.47 million or 99.2% has been subsequently collected as of the date of this filing.
As of March 31, 2022, we had outstanding bank loans of approximately $4.5 million from several PRC banks (including short-term bank loans of $1.6 million, current portion of long-term bank loans of approximately $1.8 million and long-term loan of $1.1 million). Management expects that it would be able to renew all of its existing bank loans upon their maturity based on past experience and our good credit history. In addition to the current borrowings, from December 2020 to December 2021, we secured an aggregate of $6.5 million (RMB 41 million) lines of credit with PRC banks as working capital loan (including $2.0 million line of credit with Bohai Bank for one year, $2.5 million line of credit with Shanghai Pudong Development Bank for one year and $2.0 million line of credit with Qishang Bank for three years.). As of the date of this filing, we had borrowed $2.0 million (RMB 13 million) out of these lines of credit and had the availability to borrow additional maximum loans of $4.4 million (RMB 28 million) under these lines of credit before December 2023.
Based on the current operating plan, management believes that the above-mentioned measures, including cash on hand of $1.6 million and the above mentioned $4.4 million unused line of credit, collectively will provide sufficient liquidity for us to settle the tax liabilities with local government, to meet our future liquidity and capital expenditure requirement on the CIP project for at least 12 months from the date our unaudited condensed consolidated financial statements for the six months ended March 31, 2022 are issued.
The following table sets forth summary of our cash flows for the periods indicated:
In the Six Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Net cash provided by (used in) operating activities | $ | (130,577 | ) | $ | 1,999,769 | |||
| Net cash used in investing activities | (1,991,580 | ) | (715 | ) | ||||
| Net cash provided by (used in) financing activities | 1,824,454 | (947,501 | ) | |||||
| Effect of exchange rate change on cash | 2,915 | (64,052 | ) | |||||
| Net increase (decrease) in cash | (294,788 | ) | 987,501 | |||||
| Cash, beginning of period | 1,903,867 | 53,106 | ||||||
| Cash, end of period | $ | 1,609,079 | $ | 1,040,607 | ||||
Cash flows from operating activities
Net cash used in operating activities during the six months ended March 31, 2022 was $130,577, primarily attributable to net income of $2,529,660 for the six months ended March 31, 2022, our taxes payable decreased by $1,806,543 primarily due to income and VAT tax paid in March 2022, an increase of $1,265,109 account receivable due to increased sales in the six months ended March 31, 2022, and an increase in inventory of $515,690 due to increase of the raw materials stockpile in order to prepare for anticipated increase in production to fulfill increased sales orders from customers, offset by a decrease of $977,033 in advance payment to suppliers for raw material purchase.
Net cash provided by operating activities during the six months ended March 31, 2021 was $1,999,769, primarily attributable to (i) net income of $2,295,199 in the six months ended March 31, 2021; (ii) an increase of $2,898,493 account receivable due to increased sales in the six months ended March 31, 2021. The Company had outstanding accounts receivable of approximately $8.9 million as of March 31, 2020, of which approximately $8.7 million or 97.4% has been subsequently collected as of the date of this filing and the remaining balance is expected to be collected in August, 2021; (iii) a decrease of $1,738,442 in advance to suppliers for raw material purchase as the Company received purchased raw materials from suppliers during six months ended March 31, 2021; and (iv) an increase of $1,120,847 in tax payable mostly due to accrued and unpaid value added tax and income tax payable. As of March 31, 2021, we had approximately $5.7 million tax liabilities, mostly related to the unpaid value added tax and income tax in China. The Company initially expected to settle the unpaid income tax liabilities in May 2021 when the 2020 annual income tax return is to be filed with local tax authority, and settle the unpaid VAT tax liabilities before September 30, 2021. However, in accordance with notices issued by the government to encourage IPO of local companies, for the unpaid tax liabilities, management has discussed with local tax authorities and expects to settle the tax liabilities with no penalty before December 31, 2021.
Cash flows from investing activities
Net cash used in investing activities during the six months ended March 31, 2022 was $1,991,580 which was primarily attributable to (i) capital expenditure on construction-in-progress in the amount of $3,577,995. As of March 31, 2022, we had two CIP projects associated with construction of new manufacturing facilities in Tongchuan and Yumen City, respectively (see Note 8), these CIP projects are expected to be completed in late 2022. Our future minimum capital expenditures on these two CIP projects are estimated to be approximately $2.0 million, among which approximately $1.0 million is required for the next 12 months; (2) purchase of short-term investments in the amount of $3,678,199 because we purchased wealth management financial products from PRC banks to earn investment income and (iii) partially offset by proceeds upon redemption of short-term investments in the amount of $5,273,186.
Net cash used in investing activities during the six months ended March 31, 2021 was $715 attributable to the purchase of property and equipment.
Cash flows from financing activities
Net cash provided by financing activities during the six months ended March 31, 2022 was $1,824,454, primarily include proceeds from short-term loans of $1,608,378, proceeds from long-term loans of $594,864, offset by repayment of long-term loans of $339,343.
Net cash used in financing activities during the six months ended March 31, 2021 was $947,501, primarily include repayment of borrowings from related parties of $1,391,813, repayment of third-party loans of $716,574, repayment of short-term loans of $457,729 and payment for deferred initial public offering costs of $155,557, offset by proceeds from short-term loans of $943,517 and proceeds from long-term loans of $685,067.
During the six months ended March 31, 2022, we experienced a net decrease in cash of $294,788 as compared to 2021.
Off Balance Sheet Arrangements
As of March 31, 2022, there were no off-balance sheet arrangements.
Tabular Disclosure of Contractual Obligations
As of March 31, 2022, we had the following contractual obligations:
| Payments Due by Period | ||||||||||||||||||||
| Contractual Obligations | Total | Less than 1 year | 1-3 years | 3-5 years | More than 5 years | |||||||||||||||
| (1) Debt Obligations | $ | 4,541,180 | $ | 3,460,778 | $ | 1,080,402 | $ | - | $ | - | ||||||||||
| (2) Lease Obligations | $ | 296,861 | 183,383 | 113,478 | - | - | ||||||||||||||
| (3) Capital expenditure commitment obligations on CIP project | $ | 2,009,653 | $ | 1,038,519 | $ | - | 971,134 | - | ||||||||||||
| Total | $ | 6,847,694 | $ | 4,682,680 | $ | 1,193,880 | $ | 971,134 | $ | - | ||||||||||
(1) As of March 31, 2022, we had total $4,541,180 short-term and long-term borrowings from several PRC banks and financing institutions (including short-term loans of $1,615,503, current portion of long-term loans of $1,845,275 and long-term loans of $1,080,402) (see Footnote 10 – Debt, for details).
(2) A two-year capital lease agreement with Taizhongyin Finance Lease (Suzhou) Ltd. (“the Lessor”), as well as operating lease of our factory space in Dali and office space in Xi’an.
(3) Construction-in-progress (“CIP”) represents direct costs of construction incurred for our manufacturing facilities.
On August 16, 2017, our subsidiary, Xi’an App-Chem Bio(Tech) Co.,Ltd. started to construct a new manufacturing plant in Tongchuan City (“Tongchuan Project”), Shaanxi Province, with total budget of RMB 95 million (approximately $15.0 million) for construction of the main body of the manufacturing plant, plant decoration and purchase of machinery and equipment. The total budget increased to RMB 114 million (approximately $18.0 million) on July 2, 2021 due to increased material and labor cost, as well as longer construction period caused by COVID-19 pandemic. The construction of Tongchuan Project is expected to be fully completed and put into production by December 2022.
On May 10, 2021, a subsidiary of Xi’an App-Chem, Gansu Baimeikang Bioengineering Co., Ltd. obtained a land use right and started to construct a new manufacturing plant in Yumen City (“Yumen Project”), Gansu Province, with total budget of RMB 40 million (approximately $6.3 million) for including the construction of the main body of the manufacturing plant, plant decoration and purchase of machinery and equipment. The construction of Yumen Project is expected to be fully completed and put into production by October 2022.
As of March 31, 2022, we have spent approximately RMB 130.4 million (approximately $20.6 million) on the construction of the main body of the manufacturing plants located in Tongchuan and Yumen, and future minimum capital expenditure on these two CIP projects is estimated to be approximately $2.0 million, among which approximately $1.0 million is required for the next 12 months. We currently plan to support our ongoing CIP project construction through cash flows from operations and bank borrowings.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: August 1, 2022 | Bon Natural Life Limited | |
| By: | /s/ Yongwei Hu | |
| Yongwei Hu | ||
| Chairman and Chief Executive Officer | ||
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Unaudited Financial Statements for the Six Months Ended March 31, 2022 |
Exhibit 99.1
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
| March 31, 2022 | September 30, 2021 | |||||||
| As Of | ||||||||
| March 31, 2022 | September 30, 2021 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | $ | ||||||
| Short-term investments | ||||||||
| Accounts receivable, net | ||||||||
| Inventories, net | ||||||||
| Advance to suppliers, net | ||||||||
| Acquisition deposit | ||||||||
| Prepaid expenses and other current assets | ||||||||
| TOTAL CURRENT ASSETS | ||||||||
| Property, plant and equipment, net | ||||||||
| Intangible assets, net | ||||||||
| Right-of-use lease assets, net | ||||||||
| Deferred tax assets, net | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Short-term loans | $ | $ | ||||||
| Current portion of long-term loans | ||||||||
| Accounts payable | ||||||||
| Due to related parties | ||||||||
| Taxes payable | ||||||||
| Deferred revenue | ||||||||
| Accrued expenses and other current liabilities | ||||||||
| Finance lease liabilities, current | ||||||||
| Operating lease liability, current | ||||||||
| TOTAL CURRENT LIABILITIES | $ | $ | ||||||
| Long-term loans | ||||||||
| Finance lease liabilities, noncurrent | ||||||||
| Operating lease liability, noncurrent | ||||||||
| TOTAL LIABILITIES | ||||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| EQUITY | ||||||||
| Ordinary shares, $ par value, shares authorized, and shares issued and outstanding as of March 31, 2022 and September 30, 2021, respectively | $ | $ | ||||||
| Additional paid in capital | ||||||||
| Statutory reserve | ||||||||
| Retained earnings | ||||||||
| Accumulated other comprehensive income | ||||||||
| TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY | ||||||||
| Non-controlling interest | ||||||||
| TOTAL SHAREHOLDERS’ EQUITY | ||||||||
| TOTAL LIABILITIES AND EQUITY | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
| F-1 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(UNAUDITED)
| 2022 | 2021 | |||||||
For the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| REVENUE | $ | $ | ||||||
| COST OF REVENUE | ( | ) | ( | ) | ||||
| GROSS PROFIT | ||||||||
| OPERATING EXPENSES | ||||||||
| Selling expenses | ( | ) | ( | ) | ||||
| General and administrative expenses | ( | ) | ( | ) | ||||
| Research and development expenses | ( | ) | ( | ) | ||||
| Total operating expenses | ( | ) | ( | ) | ||||
| INCOME FROM OPERATIONS | ||||||||
| OTHER INCOME (EXPENSES) | ||||||||
| Interest income | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Unrealized foreign transaction exchange loss | ( | ) | ( | ) | ||||
| Government subsidies | ||||||||
| Income from short-term investments | ||||||||
| Other income | ||||||||
| Total other income, net | ||||||||
| INCOME BEFORE INCOME TAX PROVISION | ||||||||
| INCOME TAX PROVISION | ( | ) | ( | ) | ||||
| NET INCOME | ||||||||
| Less: net loss attributable to non-controlling interest | ( | ) | ( | ) | ||||
| NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | $ | $ | ||||||
| NET INCOME | ||||||||
| OTHER COMPREHENSIVE INCOME | ||||||||
| Total foreign currency translation adjustment | ||||||||
| TOTAL COMPREHENSIVE INCOME | ||||||||
| Less: comprehensive loss attributable to non-controlling interest | ( | ) | ( | ) | ||||
| COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | $ | $ | ||||||
| EARNINGS PER SHARE | ||||||||
| Basic | $ | $ | ||||||
| Diluted | $ | $ | ||||||
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | ||||||||
| Basic | ||||||||
| Diluted | ||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| F-2 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE SIX MONTHS ENDED MARCH 31, 2022 AND 2021
(UNAUDITED)
| Common shares | Additional paid-in | Statutory | Retained | Accumulated other comprehensive | Total shareholders’ | Non- controlling | Total | |||||||||||||||||||||||||||||
| Shares | Amount | capital | reserve | earnings | loss | equity | interest | equity | ||||||||||||||||||||||||||||
| Balance at September 30, 2020 | $ | $ | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||||
| Net income (loss) | - | ( | ) | |||||||||||||||||||||||||||||||||
| Amortization of share-based compensation | - | |||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | |||||||||||||||||||||||||||||||||||
| Balance at March 31, 2021 | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||
| Balance at September 30, 2021 | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||
| Non-cash exercise of warrants | ( | ) | ||||||||||||||||||||||||||||||||||
| Amortization of stock options | - | |||||||||||||||||||||||||||||||||||
| Net income (loss) | - | ( | ) | |||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | ( | ) | |||||||||||||||||||||||||||||||||
| Balance at March 31, 2022 | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
| F-3 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| 2022 | 2021 | |||||||
For the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | $ | ||||||
| Adjustments to reconcile net income to cash provided by operating activities | ||||||||
| Allowance for doubtful accounts | ||||||||
| Depreciation and amortization | ||||||||
| Deferred income tax | ( | ) | ||||||
| Amortization of operating lease right-of-use assets | ||||||||
| Amortization of stock options | ||||||||
| Unrealized foreign currency exchange loss | ||||||||
| Gain on disposal of property and equipment | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Inventories | ( | ) | ( | ) | ||||
| Advance to suppliers, net | ||||||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Taxes payable | ( | ) | ||||||
| Deferred revenue | ( | ) | ||||||
| Accrued expenses and other current liabilities | ||||||||
| Net cash provided by (used in) operating activities | ( | ) | ||||||
| Cash flows from investing activities | ||||||||
| Purchase of short-term investments | ( | ) | ||||||
| Proceeds upon redemption of short-term investments | ||||||||
| Purchase of property and equipment | ( | ) | ( | ) | ||||
| Proceeds from sales of property and equipment | ||||||||
| Capital expenditures on construction-in-progress | ( | ) | ||||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from short-term loans | ||||||||
| Proceeds from long-term loans | ||||||||
| Repayment of short-term loans | ( | ) | ( | ) | ||||
| Repayment of long-term loans | ( | ) | ( | ) | ||||
| Proceeds from (repayment of) borrowings from related parties | ( | ) | ||||||
| Proceeds from (repayment of) third party loans | ( | ) | ||||||
| Principal payment from (repayment of) capital lease | ( | ) | ||||||
| Payment for deferred offering costs | ( | ) | ||||||
| Net cash provided by (used in) financing activities | ( | ) | ||||||
| Effect of changes of foreign exchange rates on cash | ( | ) | ||||||
| Net increase (decrease) in cash | ( | ) | ||||||
| Cash, beginning of year | ||||||||
| Cash, end of year | $ | $ | ||||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest expense | $ | $ | ||||||
| Cash paid for income tax | $ | $ | ||||||
| Supplemental disclosure of non-cash investing and financing activities | ||||||||
| Amortization of share-based compensation for initial public offering services | $ | $ | ||||||
| Right-of-use assets obtained in exchange for operating lease obligations | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| F-4 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION
Business
Bon Natural Life Limited (“Bon Natural” or the “Company”), through its wholly-owned subsidiaries, is engaged in the research and development, manufacturing and sales of functional active ingredients extracted from natural herb plants which are widely used by manufacturer customers in the functional food, personal care, cosmetic and pharmaceutical industries. The Company sells its products to customers located in both Chinese and international markets.
Organizations
Bon Natural Life Limited was incorporated as an exempted company with limited liability under the laws of the Cayman Islands on December 11, 2019.
Bon
Natural owns
Xi’an Cell and Molecule Information Technology Limited. (“Xi’an CMIT”) was formed on April 9, 2020, as a Wholly Foreign-Owned Enterprise (“WFOE”) in the People’s Republic of China (“PRC”).
Bon Natural, Tea Essence, and Xi’an CMIT are currently not engaging in any active business operations and merely acting as holding companies.
Prior
to the reorganization described below, Mr. Yongwei Hu, the chairman of the board of directors and the chief executive officer of the
Company, was the controlling shareholder of Xi’an App-Chem Bio(Tech) Co., Ltd. (“Xi’an App-Chem”), an entity
incorporated on April 23, 2006 in accordance with PRC laws. Xi’an App-Chem owns
In
addition, Xi’an App-Chem also owns majority of the equity interest in the following two entities: Xi’an Dietary Therapy Medical
Technology Co., Ltd (“Xi’an DT”) was incorporated on April 24, 2015 in accordance with PRC laws, with
On
September 27, 2021, the Company disposed Balikun to a third party for RMB
Xi’an App-Chem, together with its subsidiaries are collectively referred to as the “Bon Operating Companies” below.
Reorganization
A reorganization of our legal structure (“Reorganization”) was completed on May 28, 2020. The reorganization involved the incorporation of Bon Natural Life, Tea Essence and Xi’an CMIT, and entering into certain contractual arrangements between Xi’an CMIT, the shareholders of Bon Operating Companies and the Bon Operating Companies. Consequently, the Company became the ultimate holding company of Tea Essence, Xi’an CMIT and Bon Operating Companies.
| F-5 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION (continued)
On May 28, 2020, Xi’an CMIT entered into a series of contractual arrangements with the shareholders of the Bon Operating Companies. These agreements include, Exclusive Service Agreement, Share Pledge Agreement, Proxy Agreement, Exclusive Option Agreement, Powers of Attorney, Spousal Consent Letter, and Loan Agreement intended to guarantee the exercise of the Exclusive Option Agreements and Spouse Consents (collectively the “VIE Agreements”). Pursuant to the VIE Agreements, Xi’an CMIT has the exclusive right to provide to the Bon Operating Companies consulting services related to business operations including technical and management consulting services. The VIE Agreements are designed to provide Xi’an CMIT with the power, rights, and obligations equivalent in all material respects to those it would possess as the sole equity holder of each of the Bon Operating Companies, including control rights and the rights to the assets, property, and revenue of each of the Bon Operating Companies. As a result of our direct ownership in Xi’an CMIT and the VIE Agreements, we believe that the Bon Operating Companies should be treated as Variable Interest Entities (“VIEs”) under the Statement of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 Consolidation and we are regarded as the primary beneficiary of our VIEs. We treat our VIEs as our consolidated entities under U.S. GAAP. The Company, together with its wholly owned subsidiaries and its VIEs, is effectively controlled by the same shareholders before and after the Reorganization and therefore the Reorganization is considered as a recapitalization of entities under common control. The consolidation of the Company, its subsidiaries, and its VIEs has been accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated financial statements. Upon the completion of the Reorganization, the Company has subsidiaries in countries and jurisdictions in the PRC and Hong Kong.
On
September 8, 2021, Xi’an Youpincui Biotechnology Co., Ltd (“Xi’an Youpincui”) was formed as a Wholly Foreign-Owned
Enterprise (“WFOE”) in the PRC. Tea Essence owns
On
June 28, 2021, the Company closed its initial public offering (“IPO”) of ordinary shares, par value US$ per
share at a public offering price of $per share, and the Company’s ordinary shares started to trade on the Nasdaq Capital Market
under the ticker symbol “BON” since June 24, 2021. On July 2, 2021, the underwriters exercised its over-allotment option
to purchase an additional shares, par value US$ per share at the price of $ per share. Gross proceeds of the Company’s
IPO, including the proceeds from the sale of the over-allotment shares, totalled $
Terminating the VIE agreements for corporate restructuring
Due
to PRC legal restrictions on foreign ownership in companies that engage in online sales China, the Company originally carried out its
business through Xi’an App-Chem, a domestic PRC company holding a value-added telecommunications license, through a variable interest
entity structure, because foreign investment in the value-added telecommunication services industry in China is extensively regulated
and subject to numerous restrictions. However, the Company’s online sales have historically generated minimal revenues. On September
28, 2021, the Company’s Board of Directors approved a restructuring of the Company’s corporate structure to terminate the
original VIE contractual agreements, to convert Xi’an App-Chem from a PRC domestic company into a Sino-foreign joint venture, and
to transfer
| F-6 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Details of the subsidiaries of the Company as of March 31, 2022 were set out below:
| Name of Entity | Date of Incorporation | Place of Incorporation | % of Ownership | Principal Activities | ||||
| Bon Natural Life | Parent,
|
|||||||
| Tea Essence | ||||||||
| Xi’an CMIT | ||||||||
| Xi’an Youpincui | ||||||||
| PRC Subsidiaries: | ||||||||
| Xi’an App- Chem Bio (Tech) | ||||||||
| Bon Operating Companies (owned by Xi’an App-Chem) | ||||||||
| App-Chem Health | ||||||||
| App-Chem Ag-tech | ||||||||
| Xi’an YH | ||||||||
| App-Chem Guangzhou | ||||||||
| Tongchuan DT | ||||||||
| Xi’an DT | ||||||||
| Tianjin YHX | ||||||||
| Gansu BMK | ||||||||
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and the notes thereto for the year ended September 30, 2021 included in the Company’s Annual Report Form 20-F. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the interim period ended March 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2022.
Non-controlling interests
Non-controlling
interests represent minority shareholders’
| F-7 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Uses of estimates
In preparing the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements. and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the unaudited condensed consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, fair value of stock-based compensation, revenue recognition and realization of deferred tax assets. The inputs into the Company’s judgments and estimates consider the economic implications of COVID-19 on the Company’s critical and significant accounting estimates. Actual results could differ from those estimates.
Risks and Uncertainties
The main operation of the Company is located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.
The development and commercialization of natural and healthy extracts and compounds products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.
The Company’s operations may be further affected by the ongoing outbreak of COVID-19 pandemic., A COVID-19 resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disruption of the Company’s supply chain. The continued uncertainties associated with COVID-19 may cause the Company’s revenue and cash flows to underperform in the next 12 months. The extent of the future impact of COVID-19 is still highly uncertain and cannot be predicted as of the date the Company’s unaudited condensed consolidated financial statements are released.
Cash and cash equivalents
Cash includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other programs.
Accounts receivable, net
The
Company determines the adequacy of reserves for doubtful accounts based on individual account analysis and historical collection trend.
The Company establishes a provision for doubtful receivables when there is objective evidence that the Company may not be able to collect
amounts due. The allowance is based on management’s best estimate of specific losses on individual exposures, as well as a provision
on historical trends of collections. Actual amounts received may differ from management’s estimate of credit worthiness and the
economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined
that the collection is not probable, and $
| F-8 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Advances to Suppliers, net
Advances
to suppliers consist of balances paid to suppliers for inventory raw materials and construction materials associated with the Company’s
construction-in-progress projects that have not been provided or received. Advances to suppliers are reviewed periodically to determine
whether their carrying value has become impaired. The Company considers the assets to be impaired if the collectability of the advance
becomes doubtful. The Company uses the aging method to estimate the allowance for unrealizable balances. In addition, at each reporting
date, the Company generally determines the adequacy of allowance for doubtful accounts by evaluating all available information, and then
records specific allowances for those advances based on the specific facts and circumstances. As of March 31, 2022 and September 30,
2021,
Inventories, net
Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. The Company recorded inventory reserve of $
Short-term investments
The Company’s short-term investments consist of wealth management financial products purchased from PRC banks, which can be redeemed at any time. The banks invest the Company’s fund in certain financial instruments including money market funds, bonds or mutual funds, with floating interest rates. The carrying values of the Company’s short-term investments approximate fair value because of their short-term maturities. The interest earned is recognized in the unaudited condensed consolidated statements of income and comprehensive income over the contractual term of these investments. As of March 31, 2022 and September 30, 2021, short-term investments consisted of the following:
SCHEDULE OF SHORT-TERM INVESTMENTS
| March
31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Beginning balance | $ | $ | ||||||
| Add: purchase wealth management financial products | ||||||||
| Less: proceeds received upon maturity of short-term investments | ( | ) | ( | ) | ||||
| Foreign currency translation adjustments | ||||||||
| Ending balance of short-term investments | $ | $ | ||||||
| F-9 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Investment
income generated from short-term investments amounted to $
Fair value of financial instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
| ● | Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. | |
| ● | Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data. | |
| ● | Level 3 — inputs to the valuation methodology are unobservable. |
Unless otherwise disclosed, the fair value of the Company’s cash, short-term investment, accounts receivable, inventories, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of March 31, 2022 and September 30, 2021 based upon the short-term nature of the assets and liabilities.
The Company believes that the carrying amount of long-term loans approximates fair value at March 31, 2022 and September 30, 2021 based on the terms of the borrowings and current market rates as the rates of the borrowings are reflective of the current market rates.
Property, plant and equipment, net
Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows:
SCHEDULE OF USEFUL LIVES OF PROPERTY, PLANT AND EQUIPMENT
| Useful life | ||
| Buildings | ||
| Machinery and equipment | ||
| Automobiles | ||
| Office and electric equipment |
Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the unaudited condensed consolidated statements of income and comprehensive income in other income or expenses.
Construction-in-Progress (“CIP”)
Construction-in-progress represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress is reclassified to the appropriate category within property, plant and equipment.
| F-10 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Intangible assets, net
The
Company’s intangible assets primarily include two land use rights. A land use right in the PRC represents an exclusive right to
occupy, use and develop a piece of land during the contractual term of the land use right. The cost of a land use right is usually paid
in one lump sum at the date the right is granted. The prepayment usually covers the entire period of the land use right. The lump sum
advance payment is capitalized and recorded as land use right and then charged to expense on a straight-line basis over the period of
the right, which is normally
The
Company acquired the first land use right of
Impairment of long-lived Assets
Long-lived assets, such as property, plant and equipment, land use rights and long-term investment, are reviewed for impairment when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Recoverability of a long-lived asset or asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying value of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount that the carrying value exceeds the estimated fair value of the asset or asset group. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Assets to be disposed are reported at the lower of carrying amount or fair value less costs to sell, and are no longer depreciated. No impairment of long-lived assets was recognized as of March 31, 2022 and September 30, 2021.
Leases
ASC 842 requires that lessees recognize ROU assets and lease liabilities calculated based on the present value of lease payments for all lease agreements with terms that are greater than twelve months. ASC 842 distinguishes leases as either a finance lease or an operating lease that affects how the leases are measured and presented in the statement of operations and statement of cash flows.
For operating leases, the Company calculated ROU assets and lease liabilities based on the present value of the remaining lease payments as of the date of adoption. There were no changes in the Company’s capital lease portfolio, which are now titled “finance leases” under ASC 842.
Upon
the adoption of the new guidance on October 1, 2020, the Company recognized operating lease right of use assets and operating lease liabilities
of approximately $
On
December 25, 2020, the Company’s subsidiary, Xi’an App-Chem (the “Lessee”) entered into a sale and leaseback
agreement with Taizhongyin Finance Lease (Suzhou) Ltd. (“the Lessor”) and sold part of its plant machines with carrying value
of RMB
| F-11 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Foreign Currency Translation
The functional currency for Bon Natural is the U.S Dollar (“US$”). Tea Essence uses Hong Kong dollar as its functional currency. However, Bon Natural, and Tea Essence currently only serve as the holding companies and did not have active operations as of March 31, 2022. The Company operates its business through its subsidiaries in the PRC as of March 31, 2022. The functional currency of the Company’s subsidiaries is the Chinese Yuan (“RMB”). The Company’s consolidated financial statements have been translated into US$.
Assets and liabilities accounts are translated using the exchange rate at each reporting period end date. Equity accounts are translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the results of operations.
The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.
The following table outlines the currency exchange rates that were used in creating the unaudited condensed consolidated financial statements:
SCHEDULE OF CURRENCY EXCHANGE RATES
| March 31, 2022 | March 31, 2021 | September 30, 2021 | ||||||||||
| Period-end spot rate | US$ | US$ | US$ | |||||||||
| Average rate | US$ | US$ | US$ | |||||||||
Revenue recognition
To determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.
In accordance to ASC 606, the Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products to its customers, in which the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. All of the Company’s contracts have single performance obligation as the promise is to transfer the individual goods to customers, and there are no other separately identifiable promises in the contracts.
The Company’s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. The Company’s products are sold with no right of return and the Company does not provide other credits or sales incentive to customers. The Company’s sales are net of value added tax (“VAT”) and business tax and surcharges collected on behalf of tax authorities in respect of product sales.
| F-12 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Contract Assets and Liabilities
Payment terms are established on the Company’s pre-established credit requirements based upon an evaluation of customers’ credit. The Company did not have contract assets as of March 31, 2022 and September 30, 2021.
The
Company’s contract liability primarily relates to unsatisfied performance obligations when payment has been received from customers
before the Company’s products are delivered, and are recorded as deferred revenue on the consolidated balance sheets. Costs of
fulfilling customers’ purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are
recognized in selling, general and administrative expense when incurred. Deferred revenue amounted to $
Disaggregation of Revenues
The Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors. The Company’s disaggregation of revenues for the six months ended March 31, 2022 and 2021 are disclosed in Note 19 of the unaudited condensed consolidation financial statements.
Research and development expenses
The
Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external
costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the six months ended March
31, 2022 and 2021, research and development expense were approximately $
Selling, General and Administrative Expenses
Selling expenses represents primarily costs of payroll, benefits, commissions for sales representatives and advertising expenses. General and administrative expenses represent primarily payroll and benefits costs for administrative employees, rent and operating costs of office premises, depreciation and amortization of office facilities, professional fees and other administrative expenses.
Advertising expense
Advertising
expenses primarily relate to promotion of the Company’s brand name and products through outdoor billboards and social media such
as Weibo and WeChat. Advertising expenses are included in selling expenses in the consolidated statements of income and comprehensive
income. Advertising expenses amounted to $
Government subsidies
Government subsidies primarily relate to local government’s cash award to High and New Technology Enterprises (“HNTEs”) to encourage entrepreneurship and stimulate local economy. Such awards are granted on a case-by-case basis by local government. The Company’s subsidiary, Xi’an App-chem was approved as a HNTE and received government subsidy in the form of export sales refund and cash awards based on annual financial performance.
| F-13 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
The
Company recognizes government subsidies as other operating income when they are received because they are not subject to any past or
future conditions, there are no performance conditions or conditions of use, and they are not subject to future refunds. Government subsidies
received and recognized as other operating income totalled $
Income taxes
The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
An
uncertain tax position is recognized only if it is “more likely than not” that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.
For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. As of March 31, 2022, the Company
had income tax payable of approximately $
The Company’s subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the six months ended March 31, 2022 and 2020. As of March 31, 2022 and September 30, 2021, all of the Company’s tax returns of its PRC subsidiaries remain open for statutory examination by PRC tax authorities.
Value added tax (“VAT”)
Sales
revenue represents the invoiced value of goods, net of VAT.
For export sales, VAT is not imposed on gross sales price, and the VAT related to purchasing raw materials is refunded after the export is completed.
| F-14 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
As
of March 31, 2022, the Company had VAT tax payable of approximately $
Employee Defined Contribution Plan
The
Company’s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company’s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
unaudited condensed consolidated statements of income and comprehensive income amounted to $
On
June 23, 2020, the Company entered into consulting service agreements with three third-party consultants (collectively the “Consultants”),
pursuant to which, the Consultants will provide public listing related consulting services to the Company in connection with the Company’s
IPO. The Company issued of its ordinary shares to the Consultants in lieu of cash payment for such services. The shares
are valued at $
The Company applied ASC 718 and related interpretations in accounting for measuring the cost of share-based compensation over the period during which the consultants are required to provide services in exchange for the issued shares. Such share-based compensation has been fully amortized because the consultants have completed their services when the Company closed its IPO in June 2021. For the six months ended March 31, 2022 and 2021, and $share-based compensation expenses were recognized.
Pursuant to the Director Service Agreements with the Company’s independent directors and following the completion of the Company’s IPO, on June 23, 2021, the Company granted stock options to three independent directors to purchase an aggregate of shares of the Company’s ordinary shares, par value of $ per share, at exercise price of $ per share, as part of the compensation to these independent directors. The stock options granted shall vest in equal monthly installments for 12 months, commencing on July 1, 2021 until June 30, 2022. Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses using the straight-line method over the service period (see Note 16).
| F-15 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the six months ended March 31, 2022, option shares and underwriter warrants were considered in the diluted EPS calculation using treasury stock method. There were no diluted shares for the six months ended March 31, 2021.
SCHEDULE OF EARNINGS PER SHARE
| 2022 | 2021 | |||||||
For the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Numerator: | ||||||||
| Net income attributable to ordinary shareholders | $ | $ | ||||||
| Denominator: | ||||||||
| Weighted-average number of ordinary shares outstanding – basic | ||||||||
| Outstanding options | ||||||||
| Outstanding warrants | ||||||||
| Potentially dilutive shares from outstanding options and warrants | ||||||||
| Weighted-average number of ordinary shares outstanding – diluted | ||||||||
| Earnings per share – basic | $ | $ | ||||||
| Earnings per share – diluted | $ | $ | ||||||
Comprehensive income
Comprehensive income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the unaudited condensed consolidated statements of income and comprehensive income.
Statement of Cash Flows
In accordance with ASC 230, “Statement of Cash Flows”, cash flows from the Company’s operations are formulated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the unaudited condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the unaudited condensed consolidated balance sheets.
Segment Reporting
The Company uses the management approach in determining reportable operating segments. The management approach considers the internal reporting used by the Company’s chief operating decision maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining the Company’s reportable operating segments. Management has determined that the Company has one operating segment (See Note 17).
| F-16 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recent Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. ASU 2016-13 was subsequently amended by ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2020-02. For public entities, ASU 2016-13 and its amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. For all other entities, this guidance and its amendments will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
In October 2020, the FASB issued ASU 2020-10, “Codification Improvements to Subtopic 205-10, presentation of financial statements”. The amendments in this Update improve the codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed. ASU 2020-10 is effective for the Company for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively. An entity should apply the amendments at the beginning of the period that includes the adoption date. The Company is currently evaluating the impact of this new standard on Company’s consolidated financial statements and related disclosures.
| F-17 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 3— LIQUIDITY
As
reflected in the Company’s unaudited condensed consolidated financial statements, the Company is currently constructing two new
manufacturing plants. As of March 31, 2022, the Company had future minimum capital expenditure commitment on its construction-in-progress
(“CIP”) project of approximately $
In
assessing its liquidity, management monitors and analyzes the Company’s cash on-hand, its ability to generate sufficient revenue
sources in the future, and its operating and capital expenditure commitments. In June 2021, the Company closed its initial public offering
and received net proceeds of approximately $
As
of March 31, 2022, the Company had cash on hand of $
Based
on the current operating plan, management believes that the above-mentioned measures, including cash on hand of $
NOTE 4 — ACCOUNTS RECEIVABLE, NET
Accounts receivable, net, consists of the following:
SCHEDULE OF ACCOUNTS RECEIVABLE, NET
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Accounts receivable | $ | $ | ||||||
| Less: allowance for doubtful accounts | ( | ) | ( | ) | ||||
| Accounts receivable, net | $ | $ | ||||||
| F-18 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 — ACCOUNTS RECEIVABLE, NET (continued)
The
Company’s accounts receivable primarily includes balance due from customers when the Company’s products are sold and delivered
to customers. Approximately $
The following table summarizes the Company’s accounts receivable and subsequent collection by aging bucket:
SCHEDULE OF ACCOUNTS RECEIVABLE AND SUBSEQUENT COLLECTION BY AGING BUCKET
| Accounts Receivable by aging bucket | Balance as of March 31, 2022 | Subsequent collection | % of subsequent collection | |||||||||
| (Unaudited) | ||||||||||||
| Less than 3 months | $ | $ | % | |||||||||
| From 4 to 6 months | % | |||||||||||
| From 7 to 9 months | ||||||||||||
| From 10 to 12 months | ||||||||||||
| Over 1 year | ||||||||||||
| Total gross accounts receivable | % | |||||||||||
| Allowance for doubtful accounts | ( | ) | ||||||||||
| Accounts Receivable, net | $ | $ | % | |||||||||
Allowance for doubtful accounts movement is as follows:
SCHEDULE OF ALLOWANCE FOR DOUBTFUL ACCOUNTS
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Beginning balance | $ | $ | ||||||
| Additions | ||||||||
| Write-off uncollectible balance | ( | ) | ||||||
| Foreign currency translation adjustments | ||||||||
| Ending balance | $ | $ | ||||||
NOTE 5 – INVENTORIES, NET
Inventories, net, consist of the following:
SCHEDULE OF INVENTORIES
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Raw materials | $ | $ | ||||||
| Finished goods | ||||||||
| Inventory valuation allowance | ( | ) | ( | ) | ||||
| Total inventory, net | $ | $ | ||||||
NOTE 6 –ADVANCES TO SUPPLIERS, NET
Advances to suppliers, net, consist of the following:
SCHEDULE OF ADVANCES TO SUPPLIERS
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Advances to suppliers for inventory raw materials | $ | $ | ||||||
| Less: allowance for doubtful accounts | ||||||||
| Advances to suppliers, net | $ | $ | ||||||
| F-19 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 –ADVANCES TO SUPPLIERS, NET (continued)
September
30, 2021 advance to supplier balance has been fully realized by January 2022. For the balance as of March 31, 2022, approximately $
NOTE 7— ACQUISITION DEPOSIT
On
July 6, 2021, the Company entered into a consulting agreement with a New York based consulting firm (“the consulting firm”),
pursuant to which, the consulting firm will help the Company to (i) identify appropriate business partner candidates in New York or California
in order to jointly establish a research and development center in the United States for future new product development; (ii) find opportunities
to establish business relationship with U.S based companies with OEM demand and utilize the Company’s manufacturing strength and
capability to manufacture healthcare ingredient products for U.S companies under the OEM arrangement and (iii) help the Company to purchase
or lease appropriate commercial facilities in the U.S., etc. The consulting firm will be compensated with $
Due
to recent COVID-19 resurgence in Xi’an City and government mandatory quarantine and city lockdown, on January 20, 2022, the Company
and the consulting firm signed a supplemental agreement to lower down the required deposit from original $
As of March 31, 2022, the consulting firm has delivered a potential acquisition target to the Company, which is a small R&D firm developing anti-aging formulas. The consulting firm is now helping the Company to perform due diligence work and the Company is now negotiating the detailed terms with this acquisition target. The intended acquisition is expected to be completed around March 2023. The Company may, at its discretion, terminate the consulting agreement and request for full refund of the deposit anytime if the due diligence work fails or the final acquisition terms not reached by both parties.
NOTE 8— PROPERTY, PLANT AND EQUIPMENT, NET
Property, plant and equipment, net, consists of the following:
SCHEDULE OF PROPERTY, PLANT, AND EQUIPMENT
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Buildings | $ | $ | ||||||
| Machinery, equipment and furniture | ||||||||
| Motor Vehicles | ||||||||
| Construction-in-progress (“CIP”) (1) | ||||||||
| Subtotal | ||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||
| Property, plant and equipment, net | $ | $ | ||||||
Depreciation
expense was $
(1)
Construction-in-progress (“CIP”) represents direct costs of construction incurred for the Company’s manufacturing facilities.
On August 16, 2017, the Company’s subsidiary, Xi’an App-Chem Bio(Tech) Co.,Ltd. started to construct a new manufacturing
plant in Tongchuan City (“Tongchuan Project”), Shaanxi Province, with total budget of RMB
| F-20 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8— PROPERTY, PLANT AND EQUIPMENT, NET (continued)
On
May 10, 2021, a subsidiary of the Company’s Xi’an App-Chem, Gansu Baimeikang Bioengineering Co., Ltd. obtained a land use
right and started to construct a new manufacturing plant in Yumen City (“Yumen Project”), Gansu Province, with total budget
of RMB
As
of March 31, 2022, the Company has spent approximately RMB
As of March 31, 2022, future minimum capital expenditures on the Company’s two CIP projects are estimated as follows:
SCHEDULE OF FUTURE MINIMUM CAPITAL EXPENDITURES ON THE CONSTRUCTION-IN-PROGRESS
| Twelve months ending March 31, | Tongchuan CIP Project | Yumen CIP Project | Total | |||||||||
| 2023 | $ | $ | $ | |||||||||
| 2024 | ||||||||||||
| 2025 | ||||||||||||
| 2026 | ||||||||||||
| Total | $ | $ | $ | |||||||||
NOTE 9 – INTANGIBLE ASSETS, NET
Intangible assets, net mainly consist of the following:
SCHEDULE OF INTANGIBLE ASSETS
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Land use rights | $ | $ | ||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||
| Land use rights, net | $ | $ | ||||||
Amortization
expense was $
SCHEDULE OF AMORTIZATION EXPENSES
| Twelve months ending March 31, | Amortization expense | |||
| 2023 | $ | |||
| 2024 | ||||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| Thereafter | ||||
| Total | $ | |||
| F-21 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10— DEBT
The Company borrowed from PRC banks, other financial institutions and third-parties as working capital funds. As of March 31, 2022 and September 30, 2021, the Company’s debt consisted of the following:
(a) Short-term loans:
SCHEDULE OF SHORT-TERM LOANS
March 31, 2022 | September 30, 2021 | |||||||||
| (Unaudited) | ||||||||||
| Xi ‘an Xinchang Micro-lending Co. Ltd. (“Xinchang”) | (1) | $ | $ | |||||||
| China Construction Bank (“CCB’) | (2) | |||||||||
| Shanghai Pudong Development Bank (“SPD Bank”) | (3) | $ | $ | |||||||
| Total short-term loans | $ | $ | ||||||||
(1)
On November 4, 2020, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with Xi’an Xinchang Micro-lending
Co. Ltd. (“Xinchang”) to borrow RMB
(2)
On January 12, 2021, the Company’s subsidiary, Tongchuan DT entered into a loan agreement with China Construction Bank (“CCB’)
to borrow RMB
On
January 17, 2022, Tongchuan DT entered into another loan agreement with China Construction Bank (“CCB’) to borrow RMB
(3)
On December 6, 2021, the Company’s subsidiary, Xi’an App-Chem, obtained an approval of line of credit from Shanghai Pudong
Development Bank (“SPD Bank”) for a maximum of RMB
(b) Long-term loans:
SCHEDULE OF LONG -TERM LOANS
March 31, 2022 | September 30, 2021 | |||||||||
| (Unaudited) | ||||||||||
| Xi’an High-Tech Emerging Industry Investment Fund Partnership | (4) | |||||||||
| Webank Co., Ltd. | (5) | |||||||||
| Huaxia Bank | (6) | |||||||||
| Qishang Bank | (7) | |||||||||
| Webank Co., Ltd. | (8) | |||||||||
| China Resources Shenzhen International Investment Trust | (9) | |||||||||
| Total | ||||||||||
| Less: current portion of long-term loans | ( | ) | ( | ) | ||||||
| Total long-term loans | $ | $ | ||||||||
(4)
On June 26, 2017, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with third-party Xi’an High-tech
Emerging Industries Investment Fund Partnership (the “Lender”) to borrow RMB
| F-22 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10— DEBT (continued)
The
loan matured on June 25, 2020 and not repaid on time due to COVID-19 impact.
(5)
On January 19, 2020, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with Shenzhen Qianhai WeBank
Co., Ltd, to borrow RMB
On
February 10, 2022, Xi’an App-Chem, entered into two loan agreements with Shenzhen Qianhai WeBank Co., Ltd, to borrow an aggregate
of RMB
Loans
from Shenzhen Qianhai WeBank Co., Ltd, in the amount of RMB
(6)
On April 3, 2020, Xi’an App-Chem, obtained a line of credit approval from Huaxia Bank for a maximum of RMB
(7)
On December 10, 2020, the Company’s subsidiary, Xi’an App-Chem, obtained an approval of line of credit from Qishang Bank
Co., Ltd. (“Qishang Bank”) for a maximum of RMB
(8)
On June 20, 2021, Xi’an App-Chem’s subsidiary, Tianjin YHX, entered into a loan agreement with Shenzhen Qianhai WeBank Co.,
Ltd, to borrow RMB
On
March 14, 2022, Tianjin YHX, entered into another loan agreement with Shenzhen Qianhai WeBank Co., Ltd, to borrow RMB
Loans
from Shenzhen Qianhai WeBank Co., Ltd, in the amount of RMB
(9)
On March 1, 2021, Tianjin YHX, entered into another loan agreement with Shenzhen Qianhai WeBank Co., Ltd, to borrow RMB
For
the above-mentioned short-term and long-term loans from PRC banks and financial institutions, interest expense amounted to $
| F-23 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10— DEBT (continued)
As
of the date of this filing, the Company had the availability to borrow an aggregate of approximately $
SCHEDULE OF LINE OF CREDIT
| Name of financial institution: | Amount | |||
| Qishang Bank | $ | |||
| Bohai Bank | ||||
| SPD Bank | ||||
| Total | $ | |||
NOTE 11 — RELATED PARTY TRANSACTIONS
SCHEDULE OF DUE TO RELATED PARTIES
| (a) | Due to related parties |
| Related party relationship | March 31, 2022 | September 30, 2021 | ||||||||
| (Unaudited) | ||||||||||
| Wenhu Guo | $ | $ | ||||||||
| Yongwei Hu | ||||||||||
| Jing Liu | ||||||||||
| Sheying Wang | ||||||||||
| Yuantao Wang | ||||||||||
| Total due to related parties | $ | $ | ||||||||
| F-24 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 11 — RELATED PARTY TRANSACTIONS (continued)
As of March 31, 2022 and September 30, 2021, the balance of due to related parties was comprised of the Company’s borrowings from related parties and was used for working capital during the Company’s normal course of business. Such advance was non-interest bearing and due on demand.
(b) Loan guarantee provided by related parties
In connection with the Company’s short-term and long-term loans borrowed from PRC banks and other financial institutions, the Company’s controlling shareholder, Mr. Yongwei Hu pledged his proportionate ownership interest in Xi’an App-chem, and his personal bank savings as collateral to safeguard the Company’s borrowings from the banks and financial institutions. Mr. Yongwei Hu and his wife Ms. Jing Liu also jointly pledged their personal residence property to guarantee the Company’s certain loans (see Note 10).
NOTE 12 — TAXES
(a) Corporate Income Taxes (“CIT”)
Cayman Islands
Under the current tax laws of the Cayman Islands, Bon Natural Life Limited (“Bon Natural Life”) is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders.
Hong Kong
Tea
Essence Limited (“Tea Essence”) is incorporated in Hong Kong and is subject to profit taxes in Hong Kong at a rate of
PRC
Under
PRC CIT Law, domestic enterprises and Foreign Investment Enterprises (“FIEs”) are usually subject to a unified
CIT
is typically governed by the local tax authority in PRC. Each local tax authority at times may grant tax holidays to local enterprises
as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the six months ended March 31, 2022
and 2021 were reported at a blended reduced rate as a result of Xi’an App-chem being approved as a HNTE and enjoying a 15% reduced
income tax rate, but subsidiaries of Xi’an App-chem are subject to a 25% income tax rate. The impact of the tax holidays noted
above decreased foreign taxes by $
| F-25 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 12 — TAXES (continued)
The following table reconciles the China statutory rates to the Company’s effective tax rate for the six months ended March 31, 2022 and 2021:
SCHEDULE OF EFFECTIVE TAX RATE
| 2022 | 2021 | |||||||
For the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| PRC statutory income tax rate | % | % | ||||||
| Effect of income tax holiday | ( | )% | ( | )% | ||||
| Permanent difference | % | |||||||
| Research and development deduction | ( | )% | ( | )% | ||||
| Change in valuation allowance | % | % | ||||||
| Effective tax rate | % | % | ||||||
The components of the income tax provision (benefit) are as follows:
SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT)
For the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Current tax provision: | ||||||||
| Cayman Islands | $ | $ | ||||||
| Hong Kong | ||||||||
| China | ||||||||
| Sub-total | ||||||||
| Deferred tax provision (benefit): | ||||||||
| Cayman Islands | ||||||||
| Hong Kong | ||||||||
| China | ( | ) | ||||||
| Sub-total | ( | ) | ||||||
| Income tax provision | $ | $ | ||||||
Deferred tax assets
The Company’s deferred tax assets are comprised of the following:
SCHEDULE OF DEFERRED TAX ASSETS
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Deferred tax assets derived from allowance for doubtful accounts and net operating losses (“NOL”) | $ | $ | ||||||
| Less: valuation allowance | ( | ) | ( | ) | ||||
| Deferred tax assets | $ | $ | ||||||
The Company follows ASC 740, “Income Taxes”, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income.
| F-26 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 12 — TAXES (continued)
A
valuation allowance is provided against deferred tax assets when the Company determines that it is more likely than not that the deferred
tax assets will not be utilized in the future. The Company has subsidiaries in the PRC, among which 7 entities, including Xi’an
CMIT, App-Chem Ag-tech, App-Chem Guangzhou, Tongchuan DT, Xi’an DT, Tianjin YHX and Gansu BMK, reported recurring operating losses
since their inception and the chances for these subsidiaries that suffered recurring losses in prior period to become profitable in the
foreseeable near future and to utilize their net operating loss carry forwards were remote. Accordingly, the Company provided valuation
allowance of $
As of March 31, 2022, all of the Company’s tax returns of its PRC subsidiaries remain open for statutory examination by PRC tax authorities.
(b) Taxes payable
Taxes payable consist of the following:
SCHEDULE OF TAXES PAYABLE
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| Income tax payable | $ | $ | ||||||
| Value added tax payable | ||||||||
| Other taxes | ||||||||
| Total taxes payable | $ | $ | ||||||
As
of March 31, 2022 and September 30, 2021, Company had accrued tax liabilities of approximately $
The
Company initially expected to settle the unpaid income tax liabilities in May 2021 when the 2020 annual income tax return is to be filed
with local tax authority, and settle the unpaid VAT tax liabilities before September 30, 2021. In May 2021, the Company negotiated with
local tax authorities and submitted a settlement extension application in accordance with the notices issued by local government to encourage
enterprises to conduct public offerings. For the unpaid income tax and VAT tax liabilities, the Company obtained an approval from local
tax authority to extend the tax liability settlement date from May 2021 to December 31, 2021. In December 2021, due to recent COVID-19
resurgence which caused strict city lockdown in Xi’an where the Company is headquartered, the Company re-negotiated with local
tax authorities and submitted a settlement extension application in accordance with the notices issued by the State Administration of
Taxation to encourage micro, small and medium-sized enterprises in manufacturing industry. For the unpaid income tax and VAT tax liabilities,
the Company obtained an approval from local tax authority to further extend the tax liability settlement date from December 31, 2021
to June 30, 2022 without interest and penalty during this extended time period. The Company paid $
| F-27 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 13 — FINANCE LEASE LIABILITIES
On
December 25, 2020, the Company’s subsidiary, Xi’an App-Chem (the “Lessee”) entered into a sale and leaseback
agreement with Taizhongyin Finance Lease (Suzhou) Ltd. (“the Lessor”) and sold part of its plant machines with carrying value
of RMB
The maturities of the Company’s finance lease liabilities are as follows:
SCHEDULE OF FINANCE LEASE LIABILITIES
| US$ | ||||
| Twelve months ending March 31, | ||||
| 2022 | $ | |||
| Total | $ | |||
NOTE 14 - OPERATING LEASE
The Company entered into following lease agreements to lease its factory in Dali County, Shaanxi Province of China and its office spaces in Xi’an City, Shaanxi Province of China. The Company intend to continue these leases for the next three years.
On
January 1, 2020,
On
June 30, 2020,
Balance sheet information related to the operating lease is as follows:
SCHEDULE OF BALANCE SHEET INFORMATION RELATED TO THE OPERATING LEASE
| March 31, 2022 | September 30, 2021 |
|||||||
| (Unaudited) | ||||||||
| Operating lease assets: | ||||||||
| Operating lease right of use assets | $ | $ | 201,007 | |||||
| Total operating lease assets | 201,007 | |||||||
| Operating lease obligations: | ||||||||
| Current operating lease liabilities | 62,871 | |||||||
| Non-current operating lease liabilities | 146,703 | |||||||
| Total operating lease obligations | $ | $ | 209,574 | |||||
| F-28 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 - OPERATING LEASE (continued)
The weighted-average remaining lease term and the weighted-average discount rate of leases are as follows:
SCHEDULE OF WEIGHTED-AVERAGE REMAINING LEASE TERM AND WEIGHTED-AVERAGE DISCOUNT RATE
| March 31, 2022 | ||||
| Weighted-average remaining lease term | ||||
| Weighted-average discount rate | % | |||
The following table summarizes the maturity of operating lease liabilities as of March 31, 2022:
SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES
| 12 months ending March 31, | US$ | |||
| 2023 | $ | |||
| 2024 | ||||
| 2025 | ||||
| Total lease payments | ||||
| Less: imputed interest | ( | ) | ||
| Total lease liabilities | $ | |||
NOTE 15— SHAREHOLDERS’ EQUITY
Ordinary Shares
Bon Natural Life Limited (“Bon Natural Life”, or the “Company”) was incorporated under the laws of Cayman Islands on December 11, 2019. The authorized number of ordinary shares was shares with par value of US$ and shares were issued.
On
June 17, 2020, the Company’s shareholders approved a reverse split of the outstanding ordinary shares at a ratio of
On
June 23, 2020, the Company entered into consulting service agreements with three third-party consultants (collectively the “Consultants”),
pursuant to which, the Consultants will provide public listing related consulting services to the Company in connection with the Company’s
intended IPO effort. Such consulting services include but not limit to market research and feasibility study, business plan drafting,
reorganization, pre-listing education and tutoring, reorganization, legal and audit firm recommendation and coordination, investor referral
and pre-listing equity financing source identification and recommendations, and independent directors and audit committee candidate’s
recommendation, etc. The Company issued of its ordinary shares to the Consultants in lieu of cash payment for such services.
The shares are valued at $
Share-based compensation to consultants related to services associated with the Company’s IPO has been fully amortized as the Company closed its IPO in June 2021. For the six months ended March 31, 2022 and 2021, $and $were recognized as share-based compensation expense based on services rendered, respectively.
| F-29 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 15— SHAREHOLDERS’ EQUITY (continued)
On June 28, 2021, the Company closed its initial public offering (“IPO”) of ordinary shares, par value US$ per share at a public offering price of $ per share, and the Company’s ordinary shares started to trade on the Nasdaq Capital Market under the ticker symbol “BON” since June 24, 2021. On July 2, 2021, the underwriters exercised its over-allotment option to purchase an additional shares, par value US$ per share at the price of $ per share.
As of March 31, 2022 and September 30, 2021, the Company had and shares of ordinary shares issued and outstanding, respectively.
Underwriter warrants
In
connection with the Company’s IPO, the Company also agreed to issue to the underwriters and to register herein warrants to purchase
up to a total of
These
warrants have warrant term of
The
warrants are exercisable at any time, and from time to time, in whole or in part, commencing 180 days from the closing of the IPO. Management
determined that these warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to its own stock.
On October 1, 2021, the underwriters elected to exercise shares of warrants with cashless exercise, which
resulted in ordinary shares issued with no proceeds received
by the Company from this transaction. As of March 31, 2022,
On July 13, 2022, the underwriters elected to exercise the remaining 50,600 shares of warrants with cashless exercise, which resulted in 31,845 ordinary shares issued with no proceeds received by the Company from this transaction.
A summary of warrants activity for the years ended March 31, 2022 and September 30, 2021 was as follows:
SCHEDULE OF WARRANTS ACTIVITY
| Number of warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Fair Value | |||||||||||||
| Exercisable, September 30, 2021 | $ | |||||||||||||||
| Granted | - | $ | ||||||||||||||
| Forfeited | - | |||||||||||||||
| Exercised | - | |||||||||||||||
| Outstanding, March 31, 2022 | $ | $ | ||||||||||||||
| Exercisable, March 31, 2022 | $ | $ | ||||||||||||||
| F-30 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Non-controlling interest
The
Company’s subsidiary, Xi’an App-chem, owns majority of the equity interest in the following two entities: Xi’an Dietary
Therapy Medical Technology Co., Ltd (“Xi’an DT”) and Tianjin Yonghexiang Bio(Tech) Co., Ltd. (“Tianjin YHX”)
Non-controlling interests represent minority shareholders’
SCHEDULE OF NON-CONTROLLING INTERESTS
| Xi’an DT | Tianjin YHX | Total | ||||||||||
| As of September 30, 2021 | $ | $ | $ | |||||||||
| Net loss attributable to non-controlling interest | ( | ) | ( | ) | ( | ) | ||||||
| Foreign currency translation adjustment | ( | ) | ( | ) | ( | ) | ||||||
| As of March 31, 2022 | $ | $ | $ | |||||||||
Statutory reserve and restricted net assets
Relevant PRC laws and regulations restrict the Company’s PRC subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities’ accumulated profits may be distributed as dividends to the Company without the consent of a third party.
The
Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus
reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC
GAAP”).
The payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S GAAP differ from those in the statutory financial statements of the WFOE and its subsidiaries. Remittance of dividends by a wholly foreign-owned company out of China is subject to examination by the banks designated by State Administration of Foreign Exchange.
In light of the foregoing restrictions, the Company’s WFOE Xi’an CMIT and subsidiaries are restricted in their ability to transfer their net assets to the Company. Foreign exchange and other regulations in the PRC may further restrict the WFOE and its subsidiaries from transferring funds to the Company in the form of dividends, loans and advances.
As
of March 31, 2022 and September 30, 2021, the restricted amounts as determined pursuant to PRC statutory laws totaled $
| F-31 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
On
June 23, 2020, the Company entered into consulting service agreements with three third-party consultants (collectively the “Consultants”),
pursuant to which, the Consultants will provide public listing related consulting services to the Company in connection with the Company’s
intended IPO effort. The Company issued of its ordinary shares to the Consultants in
lieu of cash payment for such services. The shares are valued at $
The Company applied ASC 718 and related interpretations in accounting for measuring the cost of share-based compensation over the period during which the consultants are required to provide services in exchange for the issued shares. For the six months ended March 31, 2022 and 2021, and $ share-based compensation expenses were recognized and capitalized as part of the deferred initial public offering costs, respectively, then charged to shareholders’ equity upon the completion of the IPO, as the consultants’ services directly related to the Company’s intended IPO.
Pursuant to the Director Service Agreements with the Company’s independent directors and following the completion of the Company’s IPO, on June 23, 2021, the Company granted stock options to three independent directors to purchase an aggregate of shares of the Company’s ordinary shares, par value of $ per share, at exercise price of $ per share, as part of the compensation to these independent directors. The stock options granted shall vest in equal monthly installments for months, commencing on July 1, 2021 until June 30, 2022. Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses using the straight-line method over the service period. The aggregate fair value of the options granted to independent directors was $. The fair value has been estimated using the Black-Scholes pricing model with the following weighted-average assumptions: market value of underlying ordinary shares of $ per share; risk free rate of ; expected term of year; exercise price of the options of $; volatility of ; and expected future dividends of .
For the six months ended March 31, 2022 and 2021, $ and stock option expenses were recognized and charged to General and Administrative Expenses, respectively.
SCHEDULE OF STOCK OPTION ACTIVITIES
| Number of options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Fair Value | |||||||||||||
| Outstanding, September 30, 2021 | $ | $ | ||||||||||||||
| Granted | - | |||||||||||||||
| Forfeited | - | |||||||||||||||
| Exercised | - | |||||||||||||||
| Outstanding, March 31, 2022 | $ | $ | ||||||||||||||
| Exercisable, March 31, 2022 | $ | $ | ||||||||||||||
| F-32 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 17 - CONCENTRATION
A majority of the Company’s revenue and expense transactions are denominated in RMB and a significant portion of the Company and its subsidiaries’ assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People’s Bank of China (“PBOC”). Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory bodies which require certain supporting documentation in order to affect the remittance. For the six months ended March 31, 2022 and 2021, the Company’s substantial assets were located in the PRC and the Company’s substantial revenues were derived from its subsidiaries located in the PRC.
As
of March 31, 2022 and September 30, 2021, $
The
Company sells its products primarily through direct distributors in the People’s Republic of China (the “PRC”) and
to some extent, the overseas customers in European countries, North America and Middle East. For the six months ended March 31, 2022,
three customers accounted for
As
of March 31, 2022, three customers accounted for approximately
For
the six months ended March 31, 2022, two suppliers accounted for approximately
NOTE 18 - COMMITMENTS AND CONTINGENCIES
From time to time, the Company is a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the six months ended March 31, 2022 and 2021, the Company did not have any material legal claims or litigation that, individually or in aggregate, could have a material adverse impact on the Company’s consolidated financial position, results of operations and cash flows.
The
Company has an ongoing CIP project associated with the construction of a new manufacturing facility. As of March 31, 2022, future minimum
capital expenditures on the Company’s CIP project amounted to approximately $
| F-33 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 19— SEGMENT REPORTING
An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal financial reports that are provided to and regularly reviewed by the Company’s chief operating decision maker in order to allocate resources and assess performance of the segment.
The Company’s conducts its business in China through its wholly-owned subsidiaries. The Company’s subsidiary, Xi’an App-chem, is primarily engaged in the general administration and sales of the Company’s products. The subsidiaries of Xi’an App-chem are engaged in the manufacturing, research and development and raw material purchase (see Note 1).
The
Company develops, manufactures and sells products to customers located in both Chinese and international markets. The Company’s
products have similar economic characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods
of distribution. The Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated
results when making decisions about allocating resources and assessing performance of the Company, rather than by product types or geographic
area; hence the Company has only
SCHEDULE OF REVENUE BY REGION
Revenue by region
| For
the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| PRC | $ | $ | ||||||
| Overseas | ||||||||
| Total revenue | $ | $ | ||||||
SCHEDULE OF REVENUE BY PRODUCT CATEGORIES
Revenue by product categories
The summary of our total revenues by product categories for the six months ended March 31, 2022 and 2021 was as follows:
| For
the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Fragrance compounds | $ | $ | ||||||
| Health supplements (solid drinks) | ||||||||
| Bioactive food ingredients | ||||||||
| Total revenue | $ | $ | ||||||
NOTE 20 - SUBSEQUENT EVENTS
(1). Bank Loans
On May 18, 2022, Xi’an
App-Chem’s subsidiary, Tianjin YHX, entered into a loan agreement with China Construction Bank to borrow RMB
On
June 23, 2022, the Company’s subsidiary, Xi’an App-Chem, entered into a loan agreement with Beijing Bank to borrow RMB
(2). Issuance of stock options to a new Board member
On June 27, 2022, Christopher Constable resigned from the position as an Independent Director and Chairman of the Audit Committee of the Company’s Board of Directors.
Effective June 28, 2022, the Board of Directors appointed Jeffrey J. Guzy to serve as a new Independent Director and a member and Chairman of the Audit Committee of the Board. Mr. Guzy has been granted $ worth of options exercisable at $ per share, determined by reference to the Company’s closing share price on June 27, 2022. An additional $ worth of options were granted in consideration for Mr. Guzy’s service as audit committee chairman. The options shall vest and become exercisable by in equal monthly installments over the course of the director’s initial year of service.
(3). Exercise of the stock options
As disclosed in Note 16, pursuant to the Director Service Agreements with the Company’s independent directors and following the completion of the Company’s IPO, the Company granted stock options to three independent directors to purchase an aggregate of 36,000 shares of the Company’s ordinary shares, par value of $0.0001 per share, at exercise price of $0.01 per share, as part of the compensation to these independent directors. On July 4, 2022, 14,000 shares of warrants were exercised by one of the independent directors.
(4). Exercise of the warrants
As disclosed in Note 15, in connection with the Company’s IPO, the Company agreed to issue to the underwriters with warrants to purchase up to a total of 101,200 ordinary shares of the Company, with warrant terms of five years and an exercise price of $5.00 per share, among which 50,600 shares of warrants had been exercised on October 1, 2021 by cashless method, which resulted in 20,381 ordinary shares issued with no proceeds received by the Company from this transaction. Subsequently, on July 13, 2022, the underwriters elected to exercise the remaining 50,600 shares of warrants under the cashless method, which resulted in 31,845 ordinary shares issued with no proceeds received by the Company from this transaction.
| F-34 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 21— CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY
Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X require the condensed financial information of the parent company to be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded that it was applicable to the Company as the restricted net assets of the Company’s PRC subsidiaries exceeded 25% of the consolidated net assets of the Company, therefore, the financial statements for the parent company are included herein.
For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party.
The financial information of the parent company has been prepared using the same accounting policies as set out in the Company’s consolidated financial statements except that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the condensed balance sheets as “Investment in subsidiaries” and the respective profit or loss as “Equity in earnings of subsidiaries” on the condensed statements of comprehensive income.
The footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated financial statements of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S GAAP have been condensed or omitted.
The Company did not pay any dividend for the periods presented. As of March 31, 2022 and September 30, 2021, there were no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.
| F-35 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
PARENT COMPANY BALANCE SHEETS
SCHEDULE OF CONDENSED BALANCE SHEET
March 31, 2022 | September 30, 2021 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | $ | ||||||
| Acquisition deposit | ||||||||
| Due from subsidiaries | ||||||||
| Prepaid expenses and other current assets | ||||||||
| TOTAL CURRENT ASSETS | ||||||||
| NON-CURRENT ASSETS | ||||||||
| Investment in subsidiaries | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| LIABILITIES | $ | $ | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Ordinary shares, $ par value, shares authorized, and shares issued and outstanding as of March 31, 2022 and September 30, 2021, respectively | $ | $ | ||||||
| Additional paid-in capital | ||||||||
| Retained earnings | ||||||||
| Accumulated other comprehensive income (loss) | ||||||||
| Total Bon Natural Life Limited shareholders’ equity | ||||||||
| Total liabilities and Bon Natural Life Limited shareholders’ equity | $ | $ | ||||||
| F-36 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
PARENT COMPANY STATEMENTS OF COMPREHENSIVE INCOME
SCHEDULE OF CONDENSED INCOME STATEMENT
| For the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| General and administrative expenses | $ | ( | ) | $ | ||||
| Interest income | ||||||||
| Equity in earnings of subsidiaries | ||||||||
| NET INCOME | ||||||||
| Foreign currency translation adjustment | ||||||||
| COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | $ | $ | ||||||
| F-37 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
PARENT COMPANY STATEMENTS OF CASH FLOWS
SCHEDULE OF CONDENSED CASH FLOW STATEMENT
| For the six months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | $ | ||||||
| Adjustments to reconcile net cash flows from operating activities: | - | |||||||
| Equity in earnings of subsidiaries and | ( | ) | ( | ) | ||||
| Stock-based compensation | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Cash from subsidiaries | ||||||||
| Net cash provided by financing activities | ||||||||
| CHANGES IN CASH AND RESTRICTED CASH | ( | ) | ||||||
| CASH AND RESTRICTED CASH, beginning of period | ||||||||
| CASH AND RESTRICTED CASH, end of period | $ | $ | ||||||
| F-38 |